NCT03177343|Completed
Loading search results
Sponsor study identifier
observational
102
1 country
1
Study Start
February 2015
Actual (reported)Primary Completion
August 2015
Actual (reported)Study Completion
August 2015
Actual (reported)Staphylococcus aureus represents the leading pathogen implicated in bone and joint infection (BJI), usually requiring prolonged combination antimicrobial therapy, which may be particularly challenging in the case of MDR bacteria and/or for patients with multiple drug intolerance. In the absence of new well-tolerated oral antistaphylococcal drugs, older antibiotics must be considered, such as the pristinamycin. However, pristinamycin is not currently licensed for treatment of staphylococcal BJI and lack of clinical data prevents it from being considered as a reliable alternative therapeutic option in current guidelines. The aim of this study is to evaluate pristinamycin (efficacy and tolerance) in the treatment of MSSA bone and joint infection (BJI).
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 2015
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 2015
Actual (reported)August 2015
Actual (reported)August 2015
Actual (reported)June 2, 2017
Actual (reported)June 6, 2017
Actual (reported)Efficacy of pristinamycin in MSSA bone and joint infection
Outcome of patients having had pristinamycin is described in this part. The follow up of the patients after termination of antimicrobial treatment is almost 80 weeks. Treatment failure included: persisting infection under appropriate antimicrobial therapy, relapse after interruption of antimicrobial therapy, septic indication for surgical revision \> 5 days after primary surgery, superinfection; and/or death, if related to the BJI or to complication of its management.
80 weeks
Tolerance of pristinamycin in MSSA bone and joint infection
45 weeks
All patients receiving pristinamycin as a part of treatment for an MSSA BJI and followed up between 2001 and 2011 in the infectious diseases department of HCL
Hospices Civils de Lyon - Hopital de la Croix Rousse - Centre de reference des infection ostéo-articulaires de Lyon
Lyon, 69004, France
102 participants (actual enrollment reported by the registry).
First Submitted
June 2, 2017
First Posted
June 6, 2017
Study Start
February 2015
Actual (reported)Consitution Of A Biological Collection From Samples From The Gut Microbiote In Patients Having A Bone Or Joint Infection Treated By A Suppressive Subcutaneous Antibiotherapy With Betalactamine
Contact the study team to confirm eligibility.
Primary Completion
August 2015
Actual (reported)Study Completion
August 2015
Actual (reported)Last Updated
June 6, 2017
Record last verified: 2017-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: